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ABSTRACT
Background: Bladder Cancer remains a major health burden, with over 10,000 new cases diagnosed annu-
ally in the UK. Around 80% of all cases are diagnosed as Non-Muscle Invasive Bladder Cancer (NMIBC), 
and 75% of patients have cancer recurrence and progression within 10 years. Patients with NMIBC are 
treated by Trans-Urethral Resection of the Bladder Tumour (TURBT), with approximately 8% of patients 
subsequently developing post-operative complications, such as bleeding, pain and infection. Currently, there 
is limited literature on the ‘normal’ pathophysiological response to TURBT for NMIBC, and predictors 
for post-operative complications. The aim of this clinical-pilot observational study was to evaluate changes 
in routine blood tests following TURBT. The objectives were to identify the ‘normal’ pathophysiological 
response after TURBT. 
Methods: 34 consecutive patients aged between 57–94 years (median age: 72), scheduled for TURBT were 
recruited after written informed consent. Venous blood samples were collected from patients pre operatively 
(baseline), and post operatively at the following time points; 30 minutes, 120 minutes and 240 minutes post-
operatively. 
Results: Following TURBT, significant decreases were seen in several haematological and biochemical 
markers: haemoglobin (p<0.01), platelets (p<0.01), erythrocytes (p<0.01), haematocrit (p<0.01), plasma vis-
cosity (p=0.002) activated partial thromboplastin time (p= 0.004), fibrinogen (p<0.01), potassium (p<0.01), 
globulin (p=0.047), alkaline phosphatase (p=0.001), and urea (p=0.001). 
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Furthermore, significant increases were observed in numerous haematological and biochemical param-
eters: leukocytes (p=0.049), neutrophil count (p=0.022), prothrombin (p=0.014), bilirubin (p= 0.004), and 
alanine transaminase (p=0.004). 
Conclusion: Significant changes to several routine blood tests occur following TURBT, and in general, 
it appeared that the most noticeable changes occurred between 30 and 120 minutes post-operatively. This 
clinical-pilot study may therefore provide a sound platform to undertake larger studies, to fully establish the 
effect of TURBT on routine blood tests, and could ultimately provide valuable information for doctors that 
may help with the clinical management of patients. (Int J Biomed Sci 2020; 16 (4): 68-74)
Keywords: Bladder Cancer; Trans-urethral Resection of the bladder Tumour (TURBT); Urology; Post-operative 
complications; Surgery; Blood tests
BACKGROUND
Bladder Cancer (BC) is one of the top ten most com-
mon cancers, which affects over 10,000 people in the UK 
annually. BC incidence is higher in men compared to 
women, presenting a 3:1 ratio (1, 2). Over 75% of BC cases 
appear in the superficial layer as Non-Muscle Invasive 
Bladder Cancer (NMIBC), and presents with high recur-
rence (60%) and Progression Rates (20%) within 10 years 
(3). Specifically, NMIBC is a papillary tumour, which 
starts to invade the lamina propria or the sub-epithelial 
connective tissue. 
Currently, the European Association of Urology (EAU) 
guidelines indicate that patients who are suspected of hav-
ing bladder cancer, must undergo Trans-Urethral Resec-
tion of the Bladder Tumour (TURBT) surgery, as a diag-
nosis for bladder cancer and subsequently a treatment for 
NMIBC. 
In 2011, 11% of TURBTs were performed as day case 
surgeries, whereas in 2014, a significant increase (68%) 
were performed as day case surgeries (4). Complication 
rates following TURBT surgeries has been reported at 
8%, with bladder perforation, pain, infection and bleed-
ing being the most common complications (5, 6). With an 
ageing population, increase in incidence rates and high re-
currence rates, it is anticipated that the number of TURBT 
will increase, and consequently will lead to an increase 
in post-operative complications, which can be appreciated 
to involve patients requiring longer hospital stays, poor 
patient experience and outcomes, and additional financial 
constraints for the NHS.
Whilst we, and others, have previously reported post-
operative changes in routine blood tests following various 
surgical procedures (7-13-17), crucially, there is very little 
evidence investigating the direct effect of TURBT, for diag-
nosis of NMIBC on routine blood tests. Specifically, Hughes 
et al., [2013] have reported that lower limb orthopaedic sur-
gery results in changes to coagulation (e.g. D-dimer) and 
non-specific inflammatory (e.g. CRP) biomarkers. During 
this study the most noticeable changes in biomarker lev-
els occurred during days 1 to 3 postoperatively, with these 
changes being suggested to influence postoperative clinical 
outcomes such as oedema, pyrexia and pain. 
With respect to urological procedures, Moyes et al., 
[2017] have reported significant changes in haematology 
(i.e. red blood cells, white blood cells, neutrophils, and 
platelet counts) and biochemistry (i.e. CRP, total protein, 
bilirubin, alkaline phosphatase, sodium and potassium) 
parameters following Flexible Ureterorenoscopy (FURS), 
for the treatment of kidney stones. During this study, it 
was concluded that some of the significant data presented 
may represent the ‘normal’ post-operative response fol-
lowing FURS, as no major complications occurred in most 
patients recruited in the study.
More recently, Hughes et al., [2020] have reported on 
changes to routine blood tests following shock wave litho-
tripsy (SWL), for the treatment of small kidney stones. In-
terestingly, the changes seen during this study followed a 
similar pattern to those reported by Moyes et al., [2017]. 
We therefore believe that by evaluating the role of routine 
blood tests following TURBT would provide a welcomed 
addition to the urological literature, to further help our un-
derstanding of the post-operative course following routine 
urological surgical procedures.
The aim of this observational study was to evaluate 
changes to routine blood tests (haematology and biochem-
istry) following TURBT. It was our expectation to enhance 
the current urological literature, by adding evidence-based 
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insight on this topic, where the results may help to identify 
the ‘normal pathophysiological’ response for patients un-
dergoing TURBT. Ultimately, this could help predict those 
at increased risk of developing post-operative complica-
tions. Subsequently, this observational study would form a 
sound basis to undertake future investigations employing 
a larger cohort, involving multi-centre institutions.
METHODS
Subject Volunteers and TURBT 
Ethical approval for this observational study was re-
ceived from the Welsh Research Ethics Service 4 Com-
mittee (REC4:14/WA/0033), UK. Thirty-four consecutive 
patients who underwent TURBT surgery, for the diagnosis 
of NMIBC were recruited after written informed consent 
(n=34). The patients, 28 Males and 6 Females (ratio 4.7:1), 
were aged between 57-94 years (median age: 72). Treat-
ment was given as per standardised protocol in our insti-
tution, using the Olympus system 400 resectoscope and 
TURIS bioplar diathermy, whilst under general or spinal 
anaesthesia. 
Blood Samples
Venous blood samples were collected from patients via 
the ante-cubital fossa pre-operatively on the morning of 
the procedure, which stood as a control (baseline) mea-
surement. Following TURBT, subsequent blood samples 
were collected at 30 minutes, 120 minutes and 240 minutes 
post-operatively. Three vacutainers of blood were collect-
ed, namely di-potassium ethylene diamine tetraaceticacid 
(EDTA), tri-sodium citrate and serum separator tube. All 
routine haematological and biochemical parameters were 
analysed, at the Betsi Cadwaladr University Health Board 
(BCUHB) Pathology Laboratory, Wrexham Maelor Hos-
pital, North Wales (UK), using fresh whole blood, plasma 
or serum samples.
Measurement of full blood counts
Full blood counts was performed using a Sysmex 
XE-5000 automated cell counter using blood collected in 
EDTA tubes. 
Measurement of haemostatic function 
Tri-sodium citrated blood samples were used to mea-
sure haemostatic function, namely activated partial throm-
boplastin time (aPTT) (seconds), Prothrombin Time (PT) 
(seconds) and Fibrinogen (g/L). All tests were undertaken 
employing a Sysmex CS2100 analyser. 
Measurement of plasma viscosity (PV) 
Plasma viscosity (mPa/second) was measured using 
a Benson BV200 Viscometer, from blood collected in 
EDTA tubes. 
Measurement of biochemistry parameters
Biochemistry parameters were measured using blood 
collected in serum separator tubes, employing the Beck-
man Coulter AU5800 and AU680 analysers. 
Statistical analysis 
Results were presented as mean ± standard error 
(SE) or median ± minimum/maximum. Where data was 
normally distributed repeated measure one-way analy-
sis of variance (ANOVA) between sample tests was em-
ployed, adopting a 5% level of significance. Post hoc 
testing was conducted using the Bonferroni test for 
pairwise comparisons between means. Data that did not 
comply with normality were analysed using the Fried-
man test. Where the Friedman test resulted in statistical 
significance, subsequent tests were performed using the 




Table 1 illustrates the changes observed in haematolog-
ical parameters following TURBT, for the diagnosis and 
subsequent treatment of bladder cancer (n=34). Significant 
decreases were observed post-operatively in the follow-
ing parameters: haemoglobin (p<0.01), platelets (p<0.01), 
erythrocytes (p<0.01), haematocrit (p<0.01), plasma vis-
cosity (p= 0.002) activated partial thromboplastin time 
(p= 0.004), and fibrinogen (p<0.01). Significant increases 
can be seen in the following haematological parameters, 
leukocytes (p=0.049), neutrophil count (p=0.022), and 
prothrombin (p=0.014).
Biochemical Blood Results 
Table 2 illustrates the changes observed in biochemi-
cal parameters following TURBT, for the diagnosis and 
subsequent treatment of bladder cancer (n=34). Significant 
decreases were observed within biochemical parameters 
post-operatively: potassium (p<0.01), globulin (p=0.047), 
alkaline phosphatase (p=0.001), and urea (p=0.001). Sig-
nificant increases were observed in the following bio-
chemical parameters: bilirubin (p=0.004), and alanine 
transaminase (p=0.004).
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Table 1. The effect of TURBT on haematological parameters (n=34)
Haematological Parameters Baseline 30 Minutes 120 Minutes 
Leukocytes (× 109/L) 8.05 (± 4.2/16.8) 6.85 (± 4.9/13.4) * 8.1 (±5.50/15.30)
Haemoglobin (g/L) 146.50( ± 96/181) 131.50 (± 95/149) * 136.0 (± 86/169)*
Platelets (× 109/L) 240.5 (±148/527) 220.0 (±124/412) * 226.0 (± 143/433)*
Erythrocytes (× 109/L) 4.74 (±3.05/6.01) 4.32 (±3.20/4.95)* 4.39 (± 2.77/5.89)*
Haematocrit 0.44 (±0.29/0.52) 0.40 (±0.30/0.44)* 0.40 (± 0.26/0.51)*
Mean Cell Volume (MCV) (fl) 91.61 ± 0.72 92.15 ± 0.79 91.60 ± 0.69
Mean Cell Haemoglobin (MCH) (pg) 30.20 (±28.70/34.70) 29.90 (± 28.90/33.90)* 30.15 (±28.30/34) 
Neutrophil Count (× 109/L) 5.4 (± 2.30/14.70) 4.65 (± 3.00/12.20)* 5.9 (± 3.20/13.50)
Lymphocyte Count (× 109/L) 1.65 ± 0.09 1.52 ± 0.09 1.47 ± 0.09
Monocyte Count (× 109/L) 0.65 (± 0.20/1.50) 0.60 (± 0.10/0.90) 0.70 (± 0.10/1.10)
Eosinophil Count (× 109/L) 0.10 (±0.0/0.70) 0.10 (± 0.0/0.90) 0.10 (± 0.0/0.90)
Basophil Count (× 109/L) 0.00 (± 0.0/0.20) 0.00 (± 0.0/0.10) 0.00 (±0/0.20)
Plasma Viscosity (mPa) 1.67 (±1.44/2.03) 1.53 (±1.38/1.72)* 1.59 (± 1.39/1.81)*
PT (Seconds) 11.05 (± 10.10/13.40) 11.60 (±10.80/30.50)* 11.30 (±10.60/12.80)*
APTT (Seconds) 26.66 ± 0.55 25.98 ± 0.53 25.87 ± 0.45*
Fibrinogen (g/L) 3.55 (± 1.90/7.80) 3.10 (± 1.50/6.10)* 3.40 (± 1.70/6.50)*
Haematological Parameters 240 Minutes Trend P Value Statistical tests 
Leukocytes (× 109/L) 8.9 (±5.50/13.60) ↑ P= 0.049 Friedman + Wilcoxon
Haemoglobin (g/L) 133.5 (± 120/156)* ↓ P<0.01 Friedman + Wilcoxon
Platelets (× 109/L) 226.0 (± 140/336)* ↓ P<0.01 Friedman + Wilcoxon
Erythrocytes (× 109/L) 4.45 (± 3.96/5.07)* ↓ P<0.01 Friedman + Wilcoxon
Haematocrit 0.41 (±0.37/0.46)* ↓ P<0.01 Friedman + Wilcoxon
Mean Cell Volume (MCV) (fl) 91.21 ± 0.83 ↓ P=0.102 ANOVA
Mean Cell Haemoglobin (MCH) (pg) 30.28 (± 28.60/33.80)* ↓ P=0.012 Friedman + Wilcoxon
Neutrophil Count (× 109/L) 6.15 (± 3.20/12.50) ↑ P=0.022 Friedman + Wilcoxon
Lymphocyte Count (× 109/L) 1.51 ± 0.14 ↓ P=0.131 ANOVA
Monocyte Count (× 109/L) 0.55 (± 0.10/1.20) ↓ P=0.430 Friedman
Eosinophil Count (× 109/L) 0.15 (± 0/0.90) ↑ P=0.702 Friedman
Basophil Count (× 109/L) 0.00 (± 0.0/0.10) - P=0.733 Friedman
Plasma Viscosity (mPa) 1.53 (± 1.41/1.72)* ↓ P=0.002 Friedman + Wilcoxon
PT (Seconds) 11.73 (± 10.80/14.30) ↑ P=0.014 Friedman + Wilcoxon
APTT (Seconds) 25.55 ± 0.68 ↓ P=0.004 ANOVA + Bonferroni
Fibrinogen (g/L) 3.10 (±1.60/4.70)* ↓ P<0.01 Friedman + Wilcoxon
Data analysed via Friedman testing was presented as median ± minimum/maximum, whereas data analysed via ANOVA is presented as 
means ± standard error. Statistical significance following post-hoc analysis was represented when *p≤0.05.
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DISCUSSION
 
The aim of this clinical-pilot observational study was to 
investigate changes to routine haematological and bio-
chemical parameters in patients following TURBT sur-
gery. It was anticipated that the information gathered from 
this study, may help identify a ‘normal’ pathophysiologi-
cal response to TURBT, and may ultimately help predict 
those patients at increased risk of developing post-opera-
tive complications, such as bleeding, pain and infection. 
Bleeding is a common feature following TURBT, with 
haematuria being the most obvious manifestation. Al-
though no complications developed in any of the patients 
recruited in our study, we report that significant changes 
to several parameters pertaining to the haemostatic pro-
cess, including PT, fibrinogen, platelet and haemoglobin, 
occur following TURBT, which are indicative markers of 
bleeding. Our results compliment the work undertaken by 
Hughes et al [2013], which demonstrated an initial decrease 
in platelet counts and an increase in leucocyte counts, up 
Table 2. The effect of TURBT on biochemical parameters (n=34)
Biochemistry Baseline 30 Minutes 120 Minutes 
Sodium (mmol/L) 138 (± 127/142) 138 (± 132/142) 137 (± 130/141)
Potassium (mmol/L) 4.5 (± 3.60/6.70) 4.5 (± 3.80/5.50) 4.4 (± 3.80/5.70)
Creatinine (µmol/L) 78 (± 59/257) 75 (± 5.90/119) 76 (± 6/254)
Estimated GFR (ml/min/1.73m2) 79 (± 21/90) 84 (± 51/90) 77 (± 21/90)
C-Reactive Protein (mg/L) 3.0 (± 1/126) 4.0 (± 1/119) 3.0 (± 1/125)
Bilirubin (µmol/L) 9 (± 5/18) 9 (± 5/22) * 10 (± 5/23) *
Total Protein (g/L) 70.31 ± 0.82 60.86 ± 1.16 63.96 ± 0.73
Albumin (g/L) 41.34 ± 0.53 35.95 ± 0.70 37.83 ± 0.53
Globulin (g/L) 29 (± 20/40) 25 (± 18/33) * 26 (± 18/35)*
Alkaline Phosphate (U/L) 80 (± 51/149) 73 (± 43/118) * 77 ( ± 47/130)
Alanine Transaminase (U/L) 20 (± 7/51) 17 (± 9/83)* 17 (± 8/47)*
Urea (mmol/L) 5.9 (± 4/20.10) 5.2 (± 3.60/8.60) * 5.4 (± 3.50/19.80)* 
Biochemistry 240 Minutes Trend P Value Statistical Tests
Sodium (mmol/L) 138 (± 136/143) ↑ P=0.740 Friedman
Potassium (mmol/L) 4.1 (± 3.50/4.80) ↓ P<0.01 Friedman + Wilcoxon
Creatinine (µmol/L) 79 (± 58/121) ↑ P=0.267 Friedman
Estimated GFR (ml/min/1.73m2) 80.50 (±50/90) ↑ P=0.158 Friedman
C-Reactive Protein (mg/L) 5.0 (± 1/22) ↑ P=0.269 Friedman
Bilirubin (µmol/L) 10 (± 5/20) * ↑ P=0.004 Friedman + Wilcoxon
Total Protein (g/L) 63.16 ± 1.39 ↓ P=0.093 ANOVA
Albumin (g/L) 36.5 ± 0.69 ↓ P=0.058 ANOVA
Globulin (g/L) 26.50 (± 21/34)* ↓ P<0.01 Friedman
Alkaline Phosphate (U/L) 69.50 (± 48/106) ↓ P=0.001 Friedman + Wilcoxon
Alanine Transaminase (U/L) 17 (± 7/38) ↓ P=0.004 Friedman + Wilcoxon
Urea (mmol/L) 5.6 (± 3.7/9.0) * ↓ P=0.001 Friedman + Wilcoxon
Data analysed via Friedman testing was presented as median ± minimum/maximum, whereas data analysed via ANOVA is presented as 
means ± standard error. Statistical significance following post-hoc analysis was represented when *p≤0.05.
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to 1-3 days post lower limb orthopaedic surgeries (10). 
Similar changes of decreasing platelet and increasing 
leucocyte counts were reported following TURBT. How-
ever, the study undertaken by Hughes et al., [2013], also 
investigated several other leukocytes, inflammatory and 
endothelial markers, which were not measured during the 
present study, mainly due to financial restrictions in be-
ing able to buy the necessary assay kits. Measuring these 
additional biomarkers such as CD11b, leukocyte elastase, 
protein C and vWF would have provided more information 
and contributed further to our understanding of the post-
operative course following TURBT.
Specifically, following TURBT, changes to selective 
biological markers, such as total protein, albumin, alka-
line phosphatase, bilirubin, total leukocytes, neutrophils, 
haemoglobin, erythrocytes, fibrinogen, and plasma vis-
cosity were reported. Our group, BCUHB North Wales 
Clinical Research Centre (UK), have recently reported of 
similar changes to several routine blood parameters fol-
lowing shock wave lithotripsy (SWL) and flexible uretero-
renoscopy (FURS), for the treatment of kidney stones (13, 
14, 16, 17). Collectively, these changes in various blood 
parameters may therefore play an intrinsic role toward 
the ‘normal’ response following routine urological proce-
dures. To date, the number of studies reporting on the ef-
fect of TURBT on routine blood parameters is limited, and 
therefore our contribution provides a welcome addition to 
the literature. 
None of the patients involved during this study devel-
oped an infection or any other complications. A possible 
explanation for this could be that the urological surgeons 
involved in the study (and as part of current standard prac-
tice at our institution), administered antibiotics (Gentami-
cin) to all patients pre- and post-surgery, to minimize any 
risk of infection, and the potential of developing post-op-
erative sepsis (a systemic response to infection). Although 
none of the patients undergoing TURBT in our study de-
veloped an infection, it may be appreciated that with the 
increased number of procedures undertaken on annual 
basis, the risk of developing post-operative infections fol-
lowing TURBT will increase and pose a problem for the 
management of these patients. 
Collectively, the data from our study have shown that 
changes to several routine biochemical and haematologi-
cal parameters, such as bilirubin, fibrinogen, and platelets, 
occur following TURBT, with the most noticeable changes 
occurring during 30 and 120 minutes post-operatively for 
most biomarkers. If these results are reproduced in larger 
studies, there is a putative suggestion that these markers 
may provide a more clinically relevant assessment of the 
extent of potential complications, such as bleeding that can 
occur following TURBT. However, it may be proposed 
that changes in the measured parameters during this study 
may not be due to a single factor, but due to multiple fac-
tors, such as the effects of anaesthesia, tissue damage and 
wound repair. However, to fully understand the effects of 
these multiple factors, further studies would need to be un-
dertaken to directly investigate the effects of anaesthesia, 
tissue damage and wound repair on the measured param-
eters. However, undertaking such specific and additional 
investigations was beyond the scope and ethical limits of 
the present study, but no doubt provides a sound future 
direction to continue work in this area.
The main constraint of undertaking this observational 
clinical pilot-study was the relatively small number of pa-
tients recruited (n=34). However, the study does provide a 
sound platform for undertaking future work, which could 
be expanded to investigate the effect of TURBT on novel 
blood markers and their association with clinical outcome, 
and to have longer follow-up measurements (e.g. 12-72 
hours post-operatively), involving larger cohorts and 
multi-centres.
It would also be interesting to recruit patients undergo-
ing similar procedures, to provide an alternative control 
measure to that of using the patients themselves. In the 
present study we recruited patients who underwent gen-
eral or spinal anaesthesia; a potential direction for future 
studies could compare the effects of these anaesthetic 
agents on some of the blood biomarkers that have been 
investigated in the study. 
CONCLUSION
Significant changes to several routine blood tests oc-
cur following TURBT, and in general, it appeared that 
the most noticeable changes occurred between 30 and 120 
minutes post-operatively. This clinical-pilot study may 
therefore provide a sound platform to undertake larger 
studies, to fully establish the effect of TURBT on routine 
blood tests, and could ultimately provide valuable infor-
mation for doctors that may help with the clinical manage-
ment of patients.
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